A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination With Pembrolizumab in Melanoma Patients With Primary Resistance to an AntiPD1Containing Immunotherapy
Latest Information Update: 12 Aug 2024
At a glance
- Drugs MB 097 (Primary) ; Pembrolizumab (Primary) ; Vancomycin (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Adverse reactions
- Acronyms MELODY-1
- Sponsors Microbiotica
- 01 Aug 2024 Status changed from planning to not yet recruiting.
- 12 Apr 2023 According to a Microbiotica media release, the company has entered into a clinical trial collaboration with MSD for this study.
- 30 Jun 2021 New trial record